WO2025210584 - RECONSTITUTED HIGH DENSITY LIPOPROTEIN TREATMENT OF MYOCARDIAL INFARCTION
National phase entry is expected:
Publication Number
WO/2025/210584
Publication Date
09.10.2025
International Application No.
PCT/IB2025/053584
International Filing Date
04.04.2025
Title **
[English]
RECONSTITUTED HIGH DENSITY LIPOPROTEIN TREATMENT OF MYOCARDIAL INFARCTION
[French]
TRAITEMENT DE L'INFARCTUS DU MYOCARDE À L'AIDE D'UNE LIPOPROTÉINE DE HAUTE DENSITÉ RECONSTITUÉE
Applicants **
CSL INNOVATION PTY LTD
Inventors
DANIELLE, Duffy
GIBSON, Charles Michael
KINGWELL, Bronwyn
Priority Data
63/574,755
04.04.2024
US
63/723,388
21.11.2024
US
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
IP Australia
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| Translation |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 3949 | |
| EPO | Filing, Examination, Granting | 32266 | |
| Japan | Filing, Examination, Granting | 3229 | |
| South Korea | Filing, Examination, Granting | 4329 | |
| USA | Filing, Examination, Granting | 12790 |
Total:
56,563
Contact Us
Abstract[English]
Agents that enhance cholesterol efflux from macrophages within atherosclerotic plaques, such as reconstituted HDL formulations, and methods of treatment comprising same and uses thereof are provided for treating patients after an acute myocardial infarction (MI) event. The treatments of MI patients with the agents reduce the risk of one or more or all of CV death, a subsequent MI, and stent thrombosis-related MI (type 4b MI) in a human patient after an acute myocardial infarction (MI) event.[French]
L'invention concerne des agents qui améliorent l'efflux de cholestérol à partir de macrophages dans des plaques athéroscléreuses, telles que des formulations de HDL reconstituée, et des méthodes de traitement comprenant ceux-ci et leurs utilisations pour traiter des patients après un événement d'infarctus du myocarde aigu (IM). Les traitements de patients atteints d'IM avec les agents réduisent l'un ou plusieurs ou l'ensemble des risques de mort cardiovasculaire, d'IM ultérieur et d'IM lié à une thrombose de stent (IM de type 4b) chez un patient humain après un événement d'infarctus du myocarde aigu (MI).